Hepatitis Research Today is a free monthly online journal that collates and summarizes the latest research about Hepatitis, including details on hepatitis a, b, c, causes, symptoms.

Volume 1 (2006), Issue 3 (March)

1. Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: assessment using transient elastometry and the role of HCV genotype 3.
   Clin Infect Dis, 42(7): 1032-9. [Abstract] [Full-text]
2. High rate of spontaneous negativity for hepatitis C virus RNA after establishment of chronic infection in Alaska Natives.
   Clin Infect Dis, 42(7): 945-52. [Abstract] [Full-text]
3. Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C.
   J Infect Dis, 193(7): 931-40. [Abstract] [Full-text]
4. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan system.
   J Clin Virol, 35(4): 373-80. [Abstract] [Full-text]
5. Sensitivity of a modified version of the ARCHITECT Anti-HCV test in detecting samples with immunoblot-confirmed, low-level antibody to hepatitis C virus.
   J Clin Virol, 35(4): 368-72. [Abstract] [Full-text]
6. Adefovir added to lamivudine for hepatitis B recurrent infection in refractory B-cell chronic lymphocytic leukemia on prolonged therapy with Campath-1H.
   J Clin Virol, 35(4): 467-9. [Abstract] [Full-text]
7. Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection.
   Clin Chim Acta, 366(1): 156-62. [Abstract] [Full-text]
8. Gender differences in human immunodeficiency virus (HIV) RNA and CD4 cell counts among new entrants to HIV care.
   Clin Microbiol Infect, 12(4): 389-91. [Abstract] [Full-text]
9. Molecular tracing of Japan-indigenous hepatitis E viruses.
   J Gen Virol, 87: 949-54. [Abstract] [Full-text]
10. Acute liver damage induced by 2-nitropropane in rats: effect of diphenyl diselenide on antioxidant defenses.
    Chem Biol Interact, 160(2): 99-107. [Abstract] [Full-text]
11. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1.
    Gut, 55(4): 529-35. [Abstract] [Full-text]
12. Detection of HCV salivary antibodies by a simple and rapid test.
    J Virol Methods, 133(1): 1-5. [Abstract] [Full-text]
13. Expression of the interleukin-7 receptor alpha chain (CD127) on virus-specific CD8+ T cells identifies functionally and phenotypically defined memory T cells during acute resolving hepatitis B virus infection.
    J Virol, 80(7): 3532-40. [Abstract] [Full-text]
14. Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.
    J Virol, 80(7): 3506-14. [Abstract] [Full-text]
15. Pegylated interferon alpha-2b for patients with HCV recurrence and graft fibrosis following liver transplantation.
    Am J Transplant, 6(4): 825-33. [Abstract] [Full-text]
16. Gene expression profiles in hepatitis C virus (HCV) and HIV coinfection: class prediction analyses before treatment predict the outcome of anti-HCV therapy among HIV-coinfected persons.
    J Infect Dis, 193(8): 1172-7. [Abstract] [Full-text]
17. Identification of a novel single-stranded DNA fragment associated with human hepatitis.
    J Infect Dis, 193(8): 1089-97. [Abstract] [Full-text]
18. Anti-PCNA autoantibodies preferentially recognize C-terminal of PCNA in patients with chronic hepatitis B virus infection.
    Clin Exp Immunol, 144(1): 110-6. [Abstract] [Full-text]
19. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C.
    J Hepatol, 44(4): 686-93. [Abstract] [Full-text]
20. Immunosuppression without steroids in liver transplantation is safe and reduces infection and metabolic complications: results from a prospective multicenter randomized study.
    J Hepatol, 44(4): 710-6. [Abstract] [Full-text]
21. Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
    J Hepatol, 44(4): 679-85. [Abstract] [Full-text]
22. A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients.
    J Hepatol, 44(4): 671-8. [Abstract] [Full-text]
23. Significant improvement in the outcome of HCV-infected transplant recipients by avoiding rapid steroid tapering and potent induction immunosuppression.
    J Hepatol, 44(4): 717-22. [Abstract] [Full-text]
24. Acute hepatitis due to Mycoplasma pneumoniae infection without lung involvement in adult patients.
    J Hepatol, 44(4): 827-8. [Abstract] [Full-text]
25. Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence.
    J Hepatol, 44(4): 702-9. [Abstract] [Full-text]
26. Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis--a randomised clinical trial.
    J Hepatol, 44(4): 784-90. [Abstract] [Full-text]
27. T cell-mediated hepatic inflammation modulates adiponectin levels in mice: role of tumor necrosis factor alpha.
    Metabolism, 55(4): 555-9. [Abstract] [Full-text]
28. The risk of hepatitis A infection among healthcare workers: a review of reported outbreaks and sero-epidemiologic studies.
    J Hosp Infect, 62(4): 414-20. [Abstract] [Full-text]
29. Hepatitis vaccination among drug users.
    Vaccine, 24(15): 2702-9. [Abstract] [Full-text]
30. Update on viral hepatitis: 2005.
    Curr Opin Gastroenterol, 22(3): 241-7. [Abstract] [Full-text]
31. Autoimmune liver disease.
    Curr Opin Gastroenterol, 22(3): 234-40. [Abstract] [Full-text]
32. Drug-induced liver disease.
    Curr Opin Gastroenterol, 22(3): 223-33. [Abstract] [Full-text]
33. Cryoglobulinaemia vasculitis in patients coinfected with HIV and hepatitis C virus.
    AIDS, 20(6): 871-7. [Abstract] [Full-text]
34. Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy.
    AIDS, 20(6): 863-70. [Abstract] [Full-text]
35. S-adenosyl-L-methionine attenuates hepatotoxicity induced by agonistic Jo2 Fas antibody following CYP2E1 induction in mice.
    J Pharmacol Exp Ther, 317(1): 44-52. [Abstract] [Full-text]
36. Metabonomic evaluation of idiosyncrasy-like liver injury in rats cotreated with ranitidine and lipopolysaccharide.
    Toxicol Appl Pharmacol, 212(1): 35-44. [Abstract] [Full-text]
37. Comprehensive regression analysis of hepatitis B virus X antigen level and anti-HBx antibody titer in the sera of patients with HBV infection.
    Pathol Oncol Res, 12(1): 34-40. [Abstract] [Full-text]
38. HBsAg diagnostic kits in the detection of hepatitis B virus mutation within "a" determinant.
    Viral Immunol, 19(1): 108-14. [Abstract] [Full-text]
39. Treatment of HCV infection with interferon alpha-2b and ribavirin in a patient with X-linked lymphoproliferative syndrome.
    Eur J Pediatr, 165(5): 348-50. [Abstract] [Full-text]
40. Does hepatitis C virus affect the reactivation of hepatitis B virus following renal transplantation?
    Nephrol Dial Transplant, 21(4): 1046-52. [Abstract] [Full-text]
41. Pharmacokinetics, pharmacodynamics, and hepatitis C viral kinetics during antiviral therapy: the null responder.
    J Med Virol, 78(4): 446-51. [Abstract] [Full-text]
42. Endogenous alphaCGRP protects against concanavalin A-induced hepatitis in mice.
    Biochem Biophys Res Commun, 343(1): 152-8. [Abstract] [Full-text]
43. Relationship between hepatitis C and chronic kidney disease: results from the Third National Health and Nutrition Examination Survey.
    J Am Soc Nephrol, 17(4): 1168-74. [Abstract] [Full-text]
44. Prevalence of protective antibody against hepatitis B virus in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Vaccine, 24(16): 3095-9. [Abstract] [Full-text]
45. Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease.
    J Med Virol, 78(4): 452-8. [Abstract] [Full-text]
46. Natural history of compensated cirrhosis in the Child-Pugh class A compared between 490 patients with hepatitis C and 167 with B virus infections.
    J Med Virol, 78(4): 459-65. [Abstract] [Full-text]
47. UK acquired hepatitis E--An emerging problem?
    J Med Virol, 78(4): 473-5. [Abstract] [Full-text]
48. Analysis of the full-length genome of genotype 4 hepatitis E virus isolates from patients with fulminant or acute self-limited hepatitis E.
    J Med Virol, 78(4): 476-84. [Abstract] [Full-text]
49. Prevalence and risk factors for hepatitis C virus infection in Mongolian children: Findings from a nationwide survey.
    J Med Virol, 78(4): 466-72. [Abstract] [Full-text]
50. Impact of the quebec school-based hepatitis B immunization program and potential benefit of the addition of an infant immunization program.
    Pediatr Infect Dis J, 25(4): 372-4. [Abstract] [Full-text]
51. Hepatitis C virus genotype distribution among intravenous drug user and the general population in Hong Kong.
    J Med Virol, 78(5): 574-81. [Abstract] [Full-text]
52. Different composition of intrahepatic lymphocytes in the immune-tolerance and immune-clearance phase of chronic hepatitis B.
    J Med Virol, 78(5): 561-8. [Abstract] [Full-text]
53. Infection with hepatitis A, B, C, and delta viruses among patients with acute hepatitis in Mongolia.
    J Med Virol, 78(5): 542-50. [Abstract] [Full-text]
54. Seroprevalence of six different viruses among pregnant women and blood donors in rural and urban Burkina Faso: A comparative analysis.
    J Med Virol, 78(5): 683-92. [Abstract] [Full-text]
55. Distribution of hepatitis C virus genotypes among hemodialysis patients in Tehran--a multicenter study.
    J Med Virol, 78(5): 569-73. [Abstract] [Full-text]
56. Liver infiltrating mononuclear cells in children with type 1 autoimmune hepatitis.
    J Clin Pathol, 59(4): 417-23. [Abstract] [Full-text]
57. A systematic review of NSAIDs withdrawn from the market due to hepatotoxicity: lessons learned from the bromfenac experience.
    Pharmacoepidemiol Drug Saf, 15(4): 213-20. [Abstract] [Full-text]
58. Spontaneous reporting of hepatotoxicity associated with antiandrogens: data from the Spanish pharmacovigilance system.
    Pharmacoepidemiol Drug Saf, 15(4): 253-9. [Abstract] [Full-text]
59. Steatosis and progression of fibrosis in untreated patients with chronic hepatitis C infection.
    Hepatology, 43(4): 780-7. [Abstract] [Full-text]
60. Progression of liver fibrosis among injection drug users with chronic hepatitis C.
    Hepatology, 43(4): 788-95. [Abstract] [Full-text]
61. Progression of fibrosis in hepatitis C with and without schistosomiasis: correlation with serum markers of fibrosis.
    Hepatology, 43(4): 771-9. [Abstract] [Full-text]
62. Interferon alpha-2b with and without ribavirin in the treatment of hepatitis B e antigen-positive chronic hepatitis B: a randomized study.
    Hepatology, 43(4): 742-9. [Abstract] [Full-text]
63. Influence of donor/recipient HLA-matching on outcome and recurrence of hepatitis C after liver transplantation.
    Liver Transpl, 12(4): 644-51. [Abstract] [Full-text]
64. The association of HLA-DR13 with lower graft survival rates in hepatitis B and primary sclerosing cholangitis Caucasian patients receiving a liver transplant.
    Liver Transpl, 12(4): 600-4. [Abstract] [Full-text]
65. Living donor liver transplantation for hepatitis C-related cirrhosis: no difference in histological recurrence when compared to deceased donor liver transplantation recipients.
    Liver Transpl, 12(4): 560-5. [Abstract] [Full-text]
66. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.
    Hepatology, 43(4): 682-9. [Abstract] [Full-text]
67. A novel three-dose regimen of daclizumab in liver transplant recipients with hepatitis C: a pharmacokinetic and pharmacodynamic study.
    Liver Transpl, 12(4): 585-91. [Abstract] [Full-text]
68. Studies on hepatoprotective and antioxidant actions of Strychnos potatorum Linn. seeds on CCl4-induced acute hepatic injury in experimental rats.
    J Ethnopharmacol, 105(1): 154-60. [Abstract] [Full-text]
69. Real-time multiplex PCR assay to quantify hepatitis C virus RNA in peripheral blood mononuclear cells.
    J Virol Methods, 133(2): 195-204. [Abstract] [Full-text]
70. A cost-effective algorithm for the diagnosis of Hepatitis C virus infection and prediction of HCV viremia in Cameroon.
    J Virol Methods, 133(2): 223-6. [Abstract] [Full-text]
71. Hepatitis C virus protease gene diversity in patients coinfected with human immunodeficiency virus.
    J Virol, 80(8): 4196-9. [Abstract] [Full-text]
72. Antibody production and in vitro behavior of CD27-defined B-cell subsets: persistent hepatitis C virus infection changes the rules.
    J Virol, 80(8): 3923-34. [Abstract] [Full-text]
73. Personal view: the management of chronic hepatitis B infection.
    Aliment Pharmacol Ther, 23(7): 857-69. [Abstract] [Full-text]
74. Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity.
    Alcohol Clin Exp Res, 30(4): 709-19. [Abstract] [Full-text]
75. Geographical distribution and disease associations of the CD45 exon 6 138G variant.
    Immunogenetics, 58(2): 235-9. [Abstract] [Full-text]

© 2006-2008 Hepatitis Research Today. All Rights Reserved.